BORDEAUX, France | January 9, 2026 — FineHeart S.A., a French clinical-stage MedTech company, has secured €83 million in combined private and public financing to accelerate the clinical development and industrialization of its FlowMaker® system, an innovative Active Implantable Medical Device (AIMD) designed to treat severe heart failure. The funding includes a €35 million Series C financing and €48 million in non-dilutive European public funding under the PIIEC Tech4Cure initiative, positioning FineHeart as a future European leader in AIMDs and reinforcing Europe’s strategic ambitions in advanced medical device innovation.
Science Significance
The scientific significance of FineHeart’s announcement centers on FlowMaker®, the first fully implantable cardiac flow accelerator engineered to work in synchrony with the heart’s natural contractions. Unlike conventional left ventricular assist devices (LVADs), FlowMaker® is entirely intraventricular, preserves physiological blood flow, and operates with very low energy consumption. Its design eliminates the need for percutaneous driveline connections by using wireless transcutaneous energy transfer, significantly reducing infection risks. This approach represents a paradigm shift in mechanical circulatory support, targeting patients with advanced heart failure who are currently underserved by existing technologies.
Regulatory Significance
From a regulatory perspective, the funding enables FineHeart to progress clinical validation and industrial scale-up in alignment with stringent European and international medical device regulations. Active Implantable Medical Devices fall under high-risk regulatory classifications, requiring robust clinical evidence, design controls, and long-term safety data. The support from the PIIEC Tech4Cure program underscores regulatory confidence in FineHeart’s technology and manufacturing strategy, while reinforcing European sovereignty in critical healthcare technologies. The company’s focus on reliability, durability, and miniaturization directly addresses key regulatory expectations for AIMDs intended for chronic implantation.
Business Significance
Advertisement
Strategically, the €83 million financing marks a major inflection point for FineHeart’s growth trajectory. The Series C round attracted both new institutional investors and long-standing backers, validating the company’s technological differentiation and execution capabilities. The accompanying public funding positions FineHeart as a structuring leader of the European AIMD ecosystem, supporting not only its own product development but also broader industrial capacity. With an estimated addressable market exceeding $5 billion, the investment strengthens FineHeart’s ability to transition from clinical development to commercial readiness, while maintaining control over core intellectual property and manufacturing expertise.
Patients’ Significance
For patients suffering from severe heart failure, the implications are substantial. FlowMaker® is designed to serve individuals who are eligible for mechanical support but cannot benefit from current LVADs due to anatomical, physiological, or risk considerations. The system’s mini-invasive implantation procedure, absence of external hardware, and reduced infection risk have the potential to improve survival, quality of life, and long-term outcomes. By targeting an estimated 50,000 of the most severe heart failure patients annually, FineHeart aims to expand access to life-saving support options that are both safer and more patient-centric.
Policy Significance
At the policy level, FineHeart’s funding reflects Europe’s commitment to strengthening strategic autonomy in healthcare technologies. The PIIEC Tech4Cure initiative supports cross-border collaboration on breakthrough innovations deemed essential for public health resilience. By advancing technologies that address energy efficiency, long-term reliability, and infection reduction, the program aligns with policy objectives to improve chronic disease management while controlling healthcare system costs. FineHeart’s role as a program leader highlights how public-private partnerships can accelerate innovation in highly regulated medical device sectors.
FineHeart’s €83 million financing milestone underscores how scientific innovation, regulatory alignment, and strategic investment can converge to reshape the future of cardiovascular care. With FlowMaker® advancing toward broader clinical validation and industrial deployment, the company is well positioned to redefine standards in active implantable medical devices while contributing to European leadership in MedTech innovation. As heart failure prevalence continues to rise globally, FineHeart’s progress signals a meaningful step toward safer, more effective, and more accessible mechanical cardiac support solutions.
Source: FineHeart S.A press release
